Log In
Print this Print this

Oncoprex (FUS1 nanoparticles)

  Manage Alerts
Collapse Summary General Information
Company Genprex Inc.
DescriptionSystemically delivered nanoparticles incorporating tumor suppressor candidate 2 (TUSC2; FUS1)
Molecular Target Tumor suppressor candidate 2 (TUSC2) (FUS1)
Mechanism of Action 
Therapeutic ModalityNanotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today